Research programme: small molecule therapeutics - Pfizer/PTC Therapeutics
Latest Information Update: 04 Nov 2017
At a glance
- Originator PTC Therapeutics
- Class Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA (PO)
- 12 Aug 2009 This programme is still in active development
- 11 Jan 2007 Preclinical trials in Undefined in USA (PO)